|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Molecular Genetics |
Departments of Laboratory Medicine and Pathology (C.G., A.S., M.A.S., C.D.J.), Oncology (J.N.S., E.G., B.L.C.), and Neurology (J.H.U.), Mayo Clinic and Foundation, Rochester, MN 55905, USA
2 Address correspondence to C. David James, Division of Experimental Pathology, Mayo Clinic, 200 First Street SW, Hilton Building, Room 820-D, Rochester, MN 55905, USA (james.david{at}mayo.edu).
Abstract
We have previously described a panel of serially transplantable glioblastoma multiforme xenograft lines established by direct subcutaneous injection of patient tumor tissue in the flanks of nude mice. Here we report the characterization of four of these lines with respect to their histopathologic, genetic, and growth properties following heterotopic-to-orthotopic (flank-to-intracranial) transfer. Cells from short-term cultures, established from excised flank xenografts, were harvested and injected into the brains of nude mice (106 cells per injection). The intracranial tumors generated from these injections were all highly mitotic as well as highly invasive, but they lacked necrotic features in most instances and failed to show endothelial cell proliferation in all instances. For mice receiving injections from a common explant culture, tumor intracranial growth rate was consistent, as indicated by relatively narrow ranges in survival time. In contrast to the loss of epidermal growth factor receptor gene (EGFR) amplification in cell culture, high-level amplification and overexpression of EGFR were retained in intracranial tumors established from two EGFR-amplified flank tumors. A third intracranial tumor retained patient tumor amplification and high-level expression of platelet-derived growth factor receptor alpha gene. Because the heterotopic-to-orthotopic transfer and propagation of glioblastoma multiforme preserves the receptor tyrosine kinase (RTK) gene amplification of patient tumors, this approach should facilitate investigations for determining the extent to which RTK amplification status influences tumor response to RTK-directed therapies. The fact that such studies were carried out by using an invasive tumor model in an anatomically appropriate context should ensure a rigorous preclinical assessment of agent efficacy.
References
Aldape, K.D., Ballman, K., Furth, A., Buckner, J.C., Giannini, C., Burger, P.C., Scheithauer, B.W., Jenkins, R.B., and James, C.D. (2004) Immuno histochemical detection of EGFRvIII in high malignancy grade astrocy tomas and evaluation of prognostic significance. J. Neuropathol. Exp. Neurol. 63,700 -707.[Medline]
Antunes, L., Angioi-Duprez, K.S., Bracard, S.R., Klein-Monhoven,
N.A., Le Faou, A.E., Duprez, A.M., and Plenat, F.M. (2000)
Analysis of tissue chimerism in nude mouse brain and abdominal xenograft
models of human glioblastoma multiforme: What does it tell us about the models
and about glioblastoma biology and therapy? J. Histochem.
Cytochem. 48,847
-858.
Bernsen, H.J.J.A., Rijken, P.F.J.W., Hagemeier, N.E.M., and van der Kogel, A.J. (1999) A quantitative analysis of vascularization and perfusion of human glioma xenografts at different implantation sites. Microvasc. Res. 57,244 -257.[CrossRef][Medline]
Bigner, S.H., Humphrey, P.A., Wong, A.J., Vogelstein, B., Mark, J.,
Fried man, H.S., and Bigner, D.D. (1990) Characterization of the
epidermal growth factor receptor in human glioma cell lines and xenografts.
Cancer Res. 50,8017
-8022.
Filmus, J., Pollak, M.N., Cairncross, J.G., and Buick, R.N. (1985) Amplified, overexpressed, and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem. Biophys. Res. Commun. 131,207 -215.[CrossRef][ISI][Medline]
Ekstrand, A.J, James, C.D., Cavenee, W.K., Seliger, B., Pettersson,
R.F., and Collins, V.P. (1991) Genes for epidermal growth factor
receptor, trans forming growth factor alpha, and epidermal growth factor and
their expression in human gliomas in vivo. Cancer Res.
51,2164
-2172.
Engebraaten, O., Hjortland, G.O., Hirschberg, H., and Fodstad, O. (1999) Growth of precultured human glioma specimens in nude rat brain. J. Neurosurg. 90,125 -132.[ISI][Medline]
Finkelstein, S.D., Black, P., Nowak, T.P., Hand, C.M., Christensen, S., and Finch, P.W. (1994) Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery 34,136 -143.[Medline]
Galanis, E., Buckner, J., Kimmel, D., Jenkins, R., Alderete, B., O'Fallon, J., Wang, C.H., Scheithauer, B.W., and James, C.D. (1998) Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int. J. Oncol. 13,717 -724.[Medline]
Groves, M.D., Puduvalli, V.K., Hess, K.R., Jaeckle, K.A., Peterson,
P., Yung, W.K., and Levin, V.A. (2002) Phase II trial of
temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in
recurrent and pro gressive glioblastoma multiforme. J. Clin.
Oncol. 20,1383
-1388.
Horten, B.C., Basler, G.A., and Shapiro, W.R. (1981) Xenograft of human malignant glial tumors into brains of nude mice. A histopathological study. J. Neuropathol. Exp. Neurol. 40,493 -511.[Medline]
James, C.D., Carlbom, E., Dumanski, J., Hansen, M., Nordenskjold,
M., Collins, V.P., and Cavenee, W.K. (1988) Clonal genomic
alterations in glioma malignancy stages. Cancer Res.
48,5546
-5551.
James, C.D., Galanis, E., Frederick, L., Kimmel, D.W., Cunningham, J.M., Atherton-Skaff, P.J., O'Fallon, J.R., Jenkins, R.B., Buckner, J.C., Hunter, S.B., Olson, J.J., and Scheithauer, B.W. (1999) Tumor suppressor gene alterations in malignant gliomas: Histopathological associations and prognostic evaluation. Int. J. Oncol. 15,547 -553.[Medline]
Jeuken, J.W.M., Sprenger, S.H.E., Wesseling, P., Bernsen, H.J.J.A., Suijker buijk, R.F., Roelofs, F., Macville, M.V.E., Gilhuis, H.J., van Overbeeke, J.J., and Boerman, R.H. (2000) Genetic reflection of glioblastoma biopsy material in xenografts: Characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization. J. Neurosurg. 92,652 -658.[Medline]
Kleihues, P., and Cavenee, W.K. (Eds.) (2000) Pathology and Genetics of Tumours of the Nervous System. Lyon: International Agency for Research on Cancer.
Leuraud, P., Taillandier, T., Aguirre-Cruz, L., Medioni, J., Crinière, E., Marie, Y., Dutrillaux, A.M., Kujas, M., Duprez, A., Delattre, J.-Y., Poupon, M.-F., and Sanson, M. (2003) Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. Br. J. Cancer 89,2327 -2332.[CrossRef][Medline]
Libermann, T.A., Nusbaum, H.R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M.D., Ullrich, A., and Schlessinger, J. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313,144 -147.[CrossRef][Medline]
Mahesparan, R., Read, T.A., Lund-Johansen, M., Skaftnesmo, K.O., Bjerkvig, R., and Engebraaten, O. (2003) Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol. 105,49 -57.[Medline]
Okada, Y., Hurwitz, E.E., Esposito, J.M., Brower, M.A., Nutt, C.L.,
and Louis, D.N. (2003) Selection pressures of TP53 mutation and
microen vironmental location influence epidermal growth factor receptor gene
amplification in human glioblastomas. Cancer Res.
63,413
-416.
Pandita, A., Aldape, K.D., Zadeh, G., Guha, A., and James, C.D. (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39,29 -36.[CrossRef][Medline]
Pilkington, G.J., Bjerkvig, R., De Ridder, L., and Kaaijk, P. (1997) In vitro and in vivo models for the study of brain tumour invasion. Anticancer Res. 17,4107 -4109.[ISI][Medline]
Quang, T.S., and Brady, L.W. (2004) Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58,972 -975.[CrossRef][Medline]
Rana, M.W., Pinkerton, H., Thornton, H., and Nagy, D. (1977) Hetero transplantation of human glioblastoma multiforme and meningioma to nude mice. Proc. Soc. Exp. Biol. Med. 155,85 -88.[Medline]
Rich, J.N., Reardon, D.A., Peery, T., Dowell, J.M., Quinn, J.A.,
Penne, K.L., Wikstrand, C.J., Van Duyn, L.B., Dancey, J.E., McLendon, R.E.,
Kao, J.C., Stenzel, T.T., Rasheed, B.K.A., Tourt-Uhlig, S.E., Herndon, J.E.,
2nd, Vredenburgh, J.J., Sampson, J.H., Friedman, A.H., Bigner, D.D., and
Friedman, H.S. (2004) Phase II trial of gefitinib in recurrent
glio blastoma. J. Clin. Oncol.
22,133
-142.
Sampson, J.H., Akabani, G., Archer, G.E., Bigner, D.D., Berger,
M.S., Fried man, A.H., Friedman, H.S., Herndon, J.E., 2nd, Kunwar, S., Marcus,
S., McLendon, R.E., Paolino, A., Penne, K., Provenzale, J., Quinn, J.,
Reardon, D.A., Rich, J., Stenzel, T., Tourt-Uhlig, S., Wikstrand, C., Wong,
T., Williams, R., Yuan, F., Zalutsky, M.R., and Pastan, I. (2003)
Prog ress report of a phase I study of the intracerebral microinfusion of a
recombinant chimeric protein composed of transforming growth factor
(TGF)-
and a mutated form of the Pseudomonas exotoxin termed
PE-38 (TP-38) for the treatment of malignant brain tumors. J.
Neurooncol. 65,27
-35.[CrossRef][Medline]
Saris, S.C., Bigner, S.H., and Bigner, D.D. (1984) Intracerebral transplantation of a human glioma line in immunosuppressed rats. J. Neurosurg. 60,582 -588.[Medline]
Shapiro, W.R., Basler, G.A., Chernik, N.L., and Posner, J.B. (1979) Human brain tumor transplantation into nude mice. J. Natl. Cancer Inst. 62,447 -453.
Smith, J.S., Wang, X.Y., Qian, J., Hosek, S.M., Scheithauer, B.W., Jenkins, R.B., and James, C.D. (2000) Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendroglio mas with grade IV anaplastic features. J. Neuropathol. Exp. Neurol. 59,495 -503.[ISI][Medline]
Taillandier, L., Antunes, L., and Angioi-Duprez, K.S. (2003) Models for neuro-oncological preclinical studies: Solid orthotopic and heterotopic grafts of human gliomas into nude mice. J. Neurosci. Methods 125,147 -157.[Medline]
Thomas, C., Ely G., James, C.D., Jenkins, R., Kastan, M., Jedlicka, A., Burger, P., and Wharen, R. (2001) Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol. 101,605 -615.[Medline]
Tonn, J.C. (2002) Model systems in neurooncology. Acta Neurochir. Suppl. 83, 79-83.
von Deimling, A., von Ammon, K., Schoenfeld, D., Wiestler, O.D., Sei zinger, B.R., and Louis, D.N. (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3,19 -26.[ISI][Medline]
Wang, X.-Y., Smith, D.I., Frederick, L., and James, C.D. (1998) Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene 16,191 -195.[CrossRef][ISI][Medline]
Watanabe, K., Tachibana, O., Sata, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6, 217-223.[ISI][Medline]
Wong, A.J., Bigner, S.H., Bigner, D.D., Kinzler, K.W., Hamilton,
S.R., and Vogelstein, B. (1987) Increased expression of the
epidermal growth factor receptor gene in malignant gliomas is invariably
associated with gene amplification. Proc. Natl. Acad. Sci.
USA 84,6899
-6903.
This article has been cited by other articles:
|
|
 |
|
  E. B. Dinca, K. V. Lu, J. N. Sarkaria, R. O. Pieper, M. D. Prados, D. A. Haas-Kogan, S. R. VandenBerg, M. S. Berger, and C. D. James p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts Cancer Res., December 15, 2008; 68(24): 10034 - 10039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bryan, B. S. Paugh, D. Kapitonov, K. M. Wilczynska, S. M. Alvarez, S. K. Singh, S. Milstien, S. Spiegel, and T. Kordula Sphingosine-1-Phosphate and Interleukin-1 Independently Regulate Plasminogen Activator Inhibitor-1 and Urokinase-Type Plasminogen Activator Receptor Expression in Glioblastoma Cells: Implications for Invasiveness Mol. Cancer Res., September 1, 2008; 6(9): 1469 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Martens, Y. Laabs, H. S. Gunther, D. Kemming, Z. Zhu, L. Witte, C. Hagel, M. Westphal, and K. Lamszus Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2 Clin. Cancer Res., September 1, 2008; 14(17): 5447 - 5458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kefas, J. Godlewski, L. Comeau, Y. Li, R. Abounader, M. Hawkinson, J. Lee, H. Fine, E. A. Chiocca, S. Lawler, et al. microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma Cancer Res., May 15, 2008; 68(10): 3566 - 3572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yu, B. B. Friday, L. Yang, P. Atadja, D. Wigle, J. Sarkaria, and A. A. Adjei Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells Neuro-oncol, January 1, 2008; 10(3): 309 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Nowicki, N. Dmitrieva, A. M. Stein, J. L. Cutter, J. Godlewski, Y. Saeki, M. Nita, M. E. Berens, L. M. Sander, H. B. Newton, et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3 Neuro-oncol, January 1, 2008; 10(5): 690 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Liu, J. N. Sarkaria, C. A. Petell, G. Paraskevakou, P. J. Zollman, M. Schroeder, B. Carlson, P. A. Decker, W. Wu, C. D. James, et al. Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme Clin. Cancer Res., December 1, 2007; 13(23): 7155 - 7165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Fulci, N. Dmitrieva, D. Gianni, E. J. Fontana, X. Pan, Y. Lu, C. S. Kaufman, B. Kaur, S. E. Lawler, R. J. Lee, et al. Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses Cancer Res., October 1, 2007; 67(19): 9398 - 9406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Sarkaria, L. Yang, P. T. Grogan, G. J. Kitange, B. L. Carlson, M. A. Schroeder, E. Galanis, C. Giannini, W. Wu, E. B. Dinca, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel Mol. Cancer Ther., March 1, 2007; 6(3): 1167 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Allen, S. Vongpunsawad, T. Nakamura, C. D. James, M. Schroeder, R. Cattaneo, C. Giannini, J. Krempski, K.-W. Peng, J. M. Goble, et al. Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity Cancer Res., December 15, 2006; 66(24): 11840 - 11850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yu, B. B. Friday, J.-P. Lai, L. Yang, J. Sarkaria, N. E. Kay, C. A. Carter, L. R. Roberts, S. H. Kaufmann, and A. A. Adjei Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther., September 1, 2006; 5(9): 2378 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yacoub, M. A. Park, D. Hanna, Y. Hong, C. Mitchell, A. P. Pandya, H. Harada, G. Powis, C.-S. Chen, C. Koumenis, et al. OSU-03012 Promotes Caspase-Independent but PERK-, Cathepsin B-, BID-, and AIF-Dependent Killing of Transformed Cells Mol. Pharmacol., August 1, 2006; 70(2): 589 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Shu, B. Antalffy, J. M. F. Su, A. Adesina, C.-N. Ou, T. Pietsch, S. M. Blaney, C. C. Lau, and X.-N. Li Valproic Acid Prolongs Survival Time of Severe Combined Immunodeficient Mice Bearing Intracerebellar Orthotopic Medulloblastoma Xenografts Clin. Cancer Res., August 1, 2006; 12(15): 4687 - 4694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2264 - 2271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Rich, S. Sathornsumetee, S. T. Keir, M. W. Kieran, A. Laforme, A. Kaipainen, R. E. McLendon, M. W. Graner, B.K. A. Rasheed, L. Wang, et al. ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors Clin. Cancer Res., November 15, 2005; 11(22): 8145 - 8157. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
